Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-08-11
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00002865
- Locations
- 🇺🇸
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- St. Louis University
- Target Recruit Count
- 30
- Registration Number
- NCT00002627
- Locations
- 🇺🇸
St. Louis University Health Sciences Center, Saint Louis, Missouri, United States
Chemotherapy in Treating Patients With Retinoblastoma
- Conditions
- Retinoblastoma
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2013-06-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00002675
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: CMF regimenBiological: filgrastimProcedure: peripheral blood stem cell transplantationRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 344
- Registration Number
- NCT00002784
- Locations
- 🇦🇺
Queen Elizabeth Hospital, Adelaide, South Australia, Australia
🇦🇺Royal Prince Alfred Hospital, Sydney, Sydney, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2009-12-23
- Target Recruit Count
- 1520
- Registration Number
- NCT00002549
- Locations
- 🇵🇹
Hospitais da Universidade de Coimbra (HUC), Coimbra, Portugal
🇨🇿Institute of Hematology and Blood Transfusion, Prague, Czech Republic
🇧🇪Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: filgrastimRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 156
- Registration Number
- NCT00002704
- Locations
- 🇺🇸
West Virginia University Hospitals, Morgantown, West Virginia, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002691
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma
- Conditions
- Sarcoma
- Interventions
- Biological: filgrastimProcedure: conventional surgeryRadiation: brachytherapyRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 43
- Registration Number
- NCT00002804
- Locations
- 🇺🇸
Via Christi Regional Medical Center, Wichita, Kansas, United States
🇺🇸MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States
🇺🇸University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2004-06-30
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT00002565
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇧🇷Faculdade de Medicina do ABC, Sao Paulo, Brazil
🇨🇱Clinica Alemana, Santiago, Chile
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Radiation: low-LET electron therapyRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-06-23
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 120
- Registration Number
- NCT00002816
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Kaplan Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.